References
- Garderet L, Mazurier C, Chapel A, Ernou I, Boutin L, Holy X, et al. Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk Lymphoma 2007; 48: 2032–2041
- Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M N, Crinquette A, et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia 2007; 21: 158–163
- Corre J, Mahtouk K, Attal M, Gadelorge M, Huynh A, Fleury-Cappellesso S, et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21: 1079–1088
- Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B, et al. The role of Wnt signaling antagonist Dkk-1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–2494
- Gunn W G, Conley A, Deininger L, Olson S D, Prockop D J, Gregory C A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and IL-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 2005; 24: 986–991
- Hall C L, Kang S, MacDougald O A, Keller E T. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006; 97: 661–672
- Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy J D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106–2111
- Gregoretti M G, Gottardi D, Ghia P, Bergui L, Merico F, Marchisio P C, et al. Characterization of bone marrow stromal cells from multiple myeloma. Leuk Res 1994; 18: 675–682
- Wallace S R, Oken M M, Lunetta K L, Panoskaltsis-Mortari A, Masellis A M. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. Cancer 2001; 91: 1219–1230
- Grotewold L, Rüther U. The Wnt antagonist Dickkopf-1 is regulated by Bmp signaling and c-Jun and modulates programmed cell death. EMBO J 2002; 21: 966–975